{
    "title": "AstraZeneca's Enhertu wins keenly-anticipated U.S. breast cancer nod",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-11085201/AstraZenecas-Enhertu-wins-keenly-anticipated-U-S-breast-cancer-nod.html",
    "date": "2022-08-05",
    "keywords": [
        "cancer",
        "approval",
        "breast",
        "drug",
        "therapy",
        "her2",
        "disease",
        "grover",
        "sankyo",
        "friday",
        "fda",
        "her2low",
        "protein",
        "survival",
        "fdas",
        "reporting",
        "use",
        "enhertu",
        "way",
        "firstever",
        "food",
        "administration",
        "medicine",
        "agency",
        "varying",
        "growth",
        "spread",
        "surface",
        "latestage",
        "trial",
        "undergone",
        "round",
        "chemotherapy",
        "data",
        "conference",
        "june",
        "ovation",
        "audience",
        "group",
        "time",
        "measure",
        "progression",
        "pfs",
        "safety",
        "risk",
        "type",
        "lung",
        "scarring",
        "toxicity",
        "regulator",
        "class",
        "antibody",
        "case",
        "trastuzumab",
        "herceptin",
        "thirdline",
        "treatment",
        "decision",
        "date",
        "patient",
        "population",
        "prospect",
        "revenue",
        "astrazeneca",
        "compound",
        "deal",
        "year",
        "bangalore",
        "editing",
        "donovan",
        "christina",
        "fincher"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}